News » Eir Ventures today announced the completion of an investment in Strike Pharma

Eir Ventures today announced the completion of an investment in Strike Pharma

23 Feb, 2022 | Press Releases

See Press Release

Eir Ventures today announced the completion of an investment in Strike Pharma, a Swedish biotechnology company that is developing personalized precision medicines within the immune-oncology space. The technology offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

All news articles

Cinclus Pharma Partners with Zentiva in €220M Deal to Commercialize Linaprazan Glurate in Europe

Purpose Pharma Announces Positive CHMP Opinion for Attrogy®

Eir Ventures Invests in Purpose Pharma

Hoba Therapeutics raises EUR 23 million

Eir Ventures invests in Dania Tx

Eir Ventures celebrates 3 years anniversary

Lovisa Backemar new Principal

Eir invests in RAPP

Eir invests in GutCRINE

Eir Ventures leads €28M investment in Scenic Biotec

Eir Ventures invests in Henlez

Eir Ventures portfolio company, Pretzel Therapeutics, announces USD 72,5m series A financing

Eir Ventures invests in Hoba Therapeutics

Eir Ventures joins oversubscribed investment round in Attgeno

Eir Ventures strengthens team – appoints three new Partners

Eir Ventures joins oversubscribed investment round in Cinclus Pharma

Eir Ventures today announced the completion of an investment in Strike Pharma

Eir Ventures announces Co-investment agreement with Copenhagen University

Eir Ventures is happy to welcome two interns

Eir Ventures expands team with new principal

Eir Ventures Closes Life Science Venture Fund at EUR122 million

Eir Ventures completes investment in ArgusEye

Eir Ventures upscales with Investment Associate

Eir Ventures’ first “seedling” Synklino ApS completes oversubscribed DKK 106 million series A round

IO Biotech, Inc. Announces Pricing of Initial Public Offering

Galecto Announces Clinical Collaboration with Roche

Eir Ventures completes investment in one-carbon Therapeutics.